European Biotech Forum 2026

- Europe lacks a unified biotech strategy, similar to the US. What does a truly consolidated EU biotech strategy look like?

- Which regulatory and investment levers should be accelerated to restore competitiveness?

- How can Europe structurally close the scale-up gap from start-up to industrial rollout?

- Do Biotech 1 and 2 adequately address regulatory bottlenecks for each biotech sector? To what extent do they strengthen the biotech sector?

- Where are the inconsistencies between DGs and member states that slow implementation?

- How can Europe accelerate approvals while maintaining safety and public trust?

- How can biotech strengthen Europe’s biosecurity and systemic resilience?Are current policies sufficient to ensure robust critical medicines supply chains?

- Should biosecurity be treated as a distinct policy pillar, on par with cybersecurity?

- Industrial biotech is emerging as a key driver of decarbonisation and supply chain resilience. How effectively will the Bioeconomy Strategy translate this potential into widespread industrial adoption and enhanced competitiveness?

- How can Europe ensure supply-chain resilience while promoting circularity?

- Which regulatory adjustments are needed to accelerate industrial deployment?

- Are proposed financing instruments sufficient to support biotech scale-up in Europe?

- How can Europe prevent “inventions in Europe, scaling abroad”?

- What practical steps can shorten the path from scientific capability to market-ready solutions?

- How can Europe establish effective regulatory leadership in biotechnology?

- What governance structures are needed to overcome competence fragmentation?

- Where should expertise be sourced to guide policy effectively?